Pacira BioSciences Urges Shareholder Support Ahead of Critical Annual Meeting on June 9, 2026

Pacira BioSciences, Inc. (PCRX), a leading player in innovative non-opioid pain therapies, focuses on maximizing shareholder value through strategic governance and operational performance.

Ahead of its Annual Meeting scheduled for June 9, 2026, the company strongly encourages stockholders to support its management nominees, Christopher Christie, Samit Hirawat, MD, and Thomas Wiggans.

This notable push comes in light of the positive evaluations from respected proxy advisory firms like Institutional Shareholder Services (ISS), which have highlighted the effectiveness of Pacira's 5x30 growth strategy and the current board's operational qualifications in navigating the company towards a prosperous future.

The improvements seen at Pacira are significant, with 2025 marking a year of record revenues and gross margins.

Recent financial results showcase the company's effective execution of business strategies, including Q1 2026 revenues of $143.3 million for EXPAREL, reflecting a 5% increase year-over-year.

Such commercial achievements are complemented by ongoing developments in the pipeline, notably several study readouts anticipated throughout 2026, which underline Pacira’s commitment to innovation in pain management.

These accomplishments underscore the board's proactive approach, contrasting sharply with the unsubstantiated claims made by the nominees backed by DOMA Perpetual Capital Management LLC.

ISS’s endorsement of Pacira's current board members is rooted in their extensive expertise relevant to the company’s strategic goals.

The firm's report emphasizes that the board has demonstrated a focused commitment to enhancing corporate governance and systematically addressing challenges.

Key measures, like separating the roles of CEO and chairman, signify a strategic shift towards better alignment with shareholder interests.

In contrast, DOMA's narrow view of selling the company lacks a comprehensive strategy and has not convincingly outlined the benefits of its proposed nominees.

This assessment reinforces the belief that Pacira’s current leadership is integral to achieving sustained growth and delivering on shareholder expectations.

In addition to the strong proxy recommendations, Pacira's commitment to transparency and governance is evident as it mobilizes support against DOMA’s nominees.

It clearly articulates the risks associated with a shift in leadership that could derail progress made under the current administration.

The upcoming Annual Meeting will be a pivotal moment for the company as it seeks to maintain a management team poised to drive forward-thinking initiatives and expand its influence in the non-opioid pain management market.

As it approaches this crucial juncture, Pacira continues to prioritize shareholder engagement, emphasizing the importance of backing its current leadership team.

With an agenda focused on innovative solutions rather than reactive strategies, Pacira BioSciences stands at the forefront of its industry, committed to ensuring long-term stakeholder value amidst a dynamic market landscape.